c suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; ...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222.pdf